Vascular Ultrasound for the Cardiologist

Amer M. Johri MD MSc FRCPC FASE Associate Professor, Queen's University Kingston Ontario Canada





An Expensive Disease

- Epidemiology of cardiovascular disease
 - Leading cause of death in US, 17% of health expenditures
 - By 2030, 40.5% of the US population is projected to have some form of CVD.
- Economic Cost:
 - Between 2010 and 2030, total direct costs of CVD are projected to triple, from \$273 billion to \$818 billion.







A Challenging Diagnosis

- History & Physical
- Clinical Standard: Angiogram
 - Cost, availability, few but serious side effects
 - It's a lumenogram and may not correlated to events
- In between armamentarium of risk stratification tools available:
 - stress testing, Nuclear, Cardiac CT, Risk scores, biomarker
 - To predict morbidity and mortality
 - To identify suitability for angiography













	СІМТ		Plaque		
Accuracy for assessing atherosclerosis	х	Reflects changes in the media (ie. media largest proportion of CIMT) rather than intima	\checkmark	Generally reflective of atherosclerotic process	
Reproducibility		Difficult to reproduce at follow up due to segment location	\checkmark	Easy to relocate plaque of interest at follow-up: Good inter-observer variability demonstrated	
		Good inter- observer variability demonstrated			
Serial measures	\checkmark	Serial changes measurable	\checkmark	Serial measures quantifiable reliably	
	х	Changes in CIMT difficult to quantify in short time frame (less than one year)			
Segments measured	Х	Difficult to measure in the bulb	\checkmark	 Plaque can be measured in any segment, including bulb 	
Ease of use	\checkmark	Automated software, widely available, rapidly measured	Х	X Requires specialized software, expertise, and more time consuming	
Standardized approach	X √	Lacking, but some ASE recommendations available	Х	Lacking; has a general definition but no recommendations	



















Beyond Quantification: Could the Detection of Vulnerable Plaque defined by Composition

> Identify the Vulnerable Patient?



































Carotid artery p	laque cha	racteristics	in CAD
------------------	-----------	--------------	--------

	Significant CAD, mean ± SD (n = 284)	Non-significant CAD, mean ± SD (n = 175)	<i>P</i> -value
IMT	0.78 ± 0.2	0.72 ± 0.1	<0.0001
A	3.1 ± 1.3	2.43 ± 1	< 0.0001
РΗ	59.7 ± 45.9	38.9 ± 37.3	< 0.0001
N	1.76 ± 0.4	0.45 ± 0.6	< 0.0001
			2

Plaque characteristics for predicting CAD PPV NPV Sens Spec (%) (%) (%) (%) 75 46 46 75 CIMT TPA 72 51 65 59 72 58 76 53 MPH IPN 93 87 92 89 42

Significance

- CEUS of carotid artery plaque may be a valuable predictor of CAD and CV events
 Value in lower risk population to be determined
- Further follow up and analysis of CV outcomes will elucidate the prognostic value of carotid artery CEUS as a risk stratification tool (in progress)
- Correlation with other imaging and biomarkers











The impact of Atherosclerosis is projected to be immense, we need better stratification tools Carotid Ultrasound Plaque Quantification associated with Cardiovascular Outcomes may help to stratify patients Standardized approaches to quantification using 2D and 3D methods are now available Plaque Composition assessment using contrast and gray scale analysis may identify plaque vulnerability and hence the Vulnerable Patient